Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2018 / Article
Special Issue

Harnessing Oxidative Stress as an Innovative Target for Cancer Therapy

View this Special Issue

Research Article | Open Access

Volume 2018 |Article ID 9742154 | https://doi.org/10.1155/2018/9742154

Mei Wang, Guangwei Shi, Chunxiang Bian, Muhammad Farrukh Nisar, Yingying Guo, Yan Wu, Wei Li, Xiao Huang, Xuemei Jiang, Jörg W. Bartsch, Ping Ji, Julia Li Zhong, "UVA Irradiation Enhances Brusatol-Mediated Inhibition of Melanoma Growth by Downregulation of the Nrf2-Mediated Antioxidant Response", Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 9742154, 15 pages, 2018. https://doi.org/10.1155/2018/9742154

UVA Irradiation Enhances Brusatol-Mediated Inhibition of Melanoma Growth by Downregulation of the Nrf2-Mediated Antioxidant Response

Academic Editor: Peng Huang
Received15 May 2017
Revised09 Nov 2017
Accepted27 Nov 2017
Published18 Feb 2018


Brusatol (BR) is a potent inhibitor of Nrf2, a transcription factor that is highly expressed in cancer tissues and confers chemoresistance. UVA-generated reactive oxygen species (ROS) can damage both normal and cancer cells and may be of potential use in phototherapy. In order to provide an alternative method to treat the aggressive melanoma, we sought to investigate whether low-dose UVA with BR is more effective in eliminating melanoma cells than the respective single treatments. We found that BR combined with UVA led to inhibition of A375 melanoma cell proliferation by cell cycle arrest in the G1 phase and triggers cell apoptosis. Furthermore, inhibition of Nrf2 expression attenuated colony formation and tumor development from A375 cells in heterotopic mouse models. In addition, cotreatment of UVA and BR partially suppressed Nrf2 and its downstream target genes such as HO-1 along with the PI3K/AKT pathway. We propose that cotreatment increased ROS-induced cell cycle arrest and cellular apoptosis and inhibits melanoma growth by regulating the AKT-Nrf2 pathway in A375 cells which offers a possible therapeutic intervention strategy for the treatment of human melanoma.

1. Introduction

Malignant melanoma (MM) is one of the most prevalent cancers in the Western world and is a highly aggressive dermatological malignancy associated with poor patient prognosis. The majority of MM arise from congenital melanocytic nevi or are due to a family history of MM; however, in some cases, 50% MM can also be associated with repeated intermittent sporadic ultraviolet (UV) exposure [1, 2], mostly UVB radiation plays a dominant role in the development of malignant melanoma, but the role of UVA is still unclear and controversial [3].

The progressive accumulation of genetic and environmental alterations causes disruption of homeostatic pathways, resulting in tumor cell invasion and lymphatic or haematogenous dissemination to distant sites [4]. In addition, B-Raf gene mutations are activated in 70% of human malignant melanomas [4, 5]. Over the past decades, the incidence of malignant melanoma is steadily rising [6]. Although significant advances have been made in diagnosis and treatment of MM, therapy resistance and metastasis are still the major reasons for mortality of patients [7]. Recently, some reports showed that Nrf2 expression in melanoma is related to invasion thereby worsening melanoma-specific survival [8]. Furthermore, aberrant activation of Nrf2 has been shown to be involved in chemoresistance and radioresistance of various malignant tumors, such as glioma and gastric cancer [911]. Thus, it is highly desirable to investigate novel therapeutic strategies capable to enhance the efficacy of metastatic melanoma treatments with fewer side effects. Nrf2 suppression and subsequent low-dose UVA irradiation might be a potential auxiliary regimen for melanoma (low dose of UVA has no carcinogenesis).

Nuclear factor E2-related factor 2 (Nrf2), a transcription factor belonging to the cap‘n’collar family of leucine-zipper (b-ZIP) proteins, has been reported to play an essential role in regulation of the cellular defense against chemicals and oxidative stress [12, 13]. However, Nrf2 is highly expressed in many cancer tissues, thereby increasing an unwanted resistance against chemotherapy, and might activate cell proliferation and suppress apoptosis [14, 15]. In addition, Nrf2 is activated by numerous oncogenic signaling pathways such as the PI3K/protein kinase B (Akt) pathway [16].

Under oxidative stress conditions including chemicals, UV irradiation, and heat shock, Nrf2 binding to its upstream keap1 (Kelch-like erythroid cell-derived protein with CNC homology- (ECH-) associated protein 1) is disrupted and leads to Nrf2 nuclear translocation and consequently activates expression of cytoprotective genes such as heme oxygenase 1 (HO-1), NAD(P)H:quinone oxidoreductase-1 (NQO1), and glutathione S-transferase (GST) drug transporters to dissipate redox homoeostasis [17, 18]. Stable activation of Nrf2 increased the resistance of human breast adenocarcinoma and neuroblastoma against tert-butylhydroquinone (tBHQ) [19]. Conversely, suppression of the Nrf2-mediated antioxidant defense system sensitizes cancer cell to ionizing radiation and chemotherapeutic drugs [17, 20, 21]. Furthermore, Nrf2 knockout mice significantly enhance the sensitivity to acetaminophen hepatotoxicity [22], cisplatin-induced nephrotoxicity [23], and bleomycin-induced pulmonary injury and fibrosis [24]. Since Nrf2 hampers cancer cell treatment, it has been analyzed as a promising drug target to combat chemoresistance [14, 19] and, up to now, a few effective Nrf2 inhibitors have been reported [25].

BR is a quassinoid isolated from Brucea javanica plant and has extensive pharmacological activities such as antimalarial, anti-inflammatory, and ant-tumor activity [26], primarily due to induction of proliferation arrest and activation of cell differentiation [2729]. Recently, it was reported that BR is a potent inhibitor of Nrf2 activation thereby leading ultimately to tumor growth inhibition and ameliorated chemoresistance as in case of cisplatin [3033]. We have found that RNA interference of Nrf2 in human skin fibroblasts increases long wave UVA- (320–400 nm) mediated damage [34], while Hirota et al. showed that Nrf2−/− 3T3 mouse fibroblasts exert increased UVA-mediated apoptosis and necrosis [35].

Medium and high doses of UVA irradiation cause oxidative stress, penetrate deeply into the dermis and subcutaneous layer [36, 37], and mediate oxidative damage to biomolecules such as proteins, lipids, carbohydrates, and nucleic acids (DNA and RNA) through reactive oxygen species (ROS) triggered by endogenous photosensitization [38].

UVA exposure following 4-thiothymidine treatment markedly increased cancer cell death [39], and reactive oxidative stress inhibits distant metastasis of human melanoma cells [40]. Thus, UVA-mediated oxidative stress offers a potential source for a novel photochemotherapy. Since BR is a specific inhibitor of Nrf2, downregulation of its expression may potentiate the therapeutic effect of phototherapy in combination with an Nrf2-inhibiting drug such as BR. We therefore speculated that cotreatment of UVA radiation and BR may have synergistic effects in the treatment of melanoma.

Using BR and low-dose UVA irradiation in A375 melanoma cells, we found that cotreatment (UVA + BR) inhibited melanoma cell growth and proliferation both in vitro and in vivo and induces cell apoptosis. Suppression of Nrf2 expression causes further accumulation of cellular ROS following UVA irradiation, which in turn inhibits AKT signaling. Our experiments revealed that cotreatment of UVA and BR caused an inhibition of AKT-Nrf2 cascades and reduced melanoma growth. Thus, this cotreatment can be a novel therapeutic attempt to enhance the effectiveness of melanoma treatment with less or no side effect compared to existing treatment options.

2. Materials and Methods

2.1. Chemicals and Reagents

Dulbecco’s Modified Eagle Medium (DMEM) high glucose, DMEM without phenol red, and RPMI 1640 medium were obtained from Life Technologies (Gibco, USA). Fetal calf serum was purchased from Biological Industries (BI, Israel). Penicillin and streptomycin were obtained from North China Pharmaceutical Co. Ltd. (NCPC, China). Dimethyl sulfoxide (DMSO) and 4,6-diamidino-2-phenylindole dihydrochloride (DAPI) were obtained from Sigma. CellTiter 96 Aqueous One Solution Cell Proliferation Assay was obtained from Promega (USA). Nrf2 and NQO1 primary antibodies were purchased from Santa Cruz Biotechnology Inc. (USA). HO-1, GSTP, Bcl-2, Bcl-xL, Bax, IκBα, COX2, caspase-3, caspase-7, caspase-8, caspase-9, and PARP primary antibodies were obtained from Cell Signaling Technology (CST, USA). β-Actin antibody was purchased from Beijing Zhongshan-Golden Bridge Biological Technology (China). Annexin V-FITC Apoptosis Detection Kit was obtained from Beyotime Institute of Biotechnology (China). BR was purchased from Dingchen Technology (China).

2.2. Irradiation of Cells with UVA

UV light therapy system (Lifotronic) 365 nm (peak) spectrum lamp was used to irradiate cells (in PBS) following standard procedures, while nonirradiated cells were used as a background control (control = 0 kJ/m2). Following UVA irradiation, cells were incubated in conditional medium for the required time.

2.3. Cell Lines and Cell Culture

Human malignant melanoma A375 cell line was bought from Shanghai Cell Resource Center (Chinese Academy of Sciences, China). HaCaT cells were kindly provided by Dr. Rex M. Tyrrell (University of Bath, UK). Cells were cultured in DMEM (Gibco) high glucose or RPMI 1640 (Gibco) supplemented with 10% FBS (Biological Industries), 100 U/ml penicillin, and 150 U/ml streptomycin. Cell cultures were incubated in a humidified cell incubation chamber adjusted at 37°C with 5% CO2. BR was dissolved in DMSO and further diluted by triple distilled sterilized water, so that the DMSO content in cell culture medium was not higher than 3%.

2.4. Cell Viability Assay

Cell viability was measured by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS, 3582, Promega), which monitors cell growth in response to treatment at certain time points. A375 cells (3000 per well) were seeded into 96-well plates and incubated overnight. Cells were then treated with various concentrations of BR and UVA alone or in combinations for times indicated. After that, cells were washed twice with PBS and 100 μL MTS prepared in 10% DMEM was added and incubated for 2 hours to read the OD values at 490 nm.

2.5. Western Blot Assay

A375 cells were cultured for 24–30 h and treated with either UVA or BR or both for the indicated times. After specific time points, treated/nontreated cells were lysed in RIPA lysis buffer (Beyotime, P0013B). To detect the phosphorylation status of various proteins, cell lysates were prepared and extracted with SDS lysis buffer (Beyotime, P0013G), in the presence of 1 mM phenylmethylsulfonyl fluoride (Beyotime, ST506). Protein concentrations were measured by using the BCA protein assay kit (Beyotime, P0010), and 50 μg protein per lane was separated by SDS-PAGE and transferred to polyvinylidene difluoride membranes (PVDF). After transfer, membranes were blocked with 5% nonfat milk in TBST for 1 hour at 37°C and incubated with the respective primary antibodies overnight at 4°C. Membranes were washed three times with 1X-TBST and incubated with horseradish peroxidase-conjugated secondary antibodies. The signals were recorded by ECL reagent (Thermo Scientific) and visualized by VersaDoc imaging system (Bio-Rad, USA).

2.6. Immunofluorescence Staining with FITC and Costaining with DAPI

Cells cultured in 24-well plates were washed three times with PBS and fixed with 4% formaldehyde for 20 minutes, followed by permeabilization using 0.1% Triton X-100 in PBS for 10 minutes. After washing with PBS, cells were blocked with 1% BSA 20 minutes at room temperature. The following operations were carried out in the dark: to each well, 200 μl FITC (diluted to 1 : 30) was added and incubated for 1 hour at room temperature. After washing with PBS three times, 1 mg/ml DAPI (in 200 μl) was incubated for 20 minutes. After washing with PBS twice, cells were mounted and analyzed under a fluorescence microscope.

2.7. Flow Cytometry and Cell Cycle Analysis

A375 cells were treated with BR and UVA, and apoptotic cells were detected using an Annexin V-FITC Apoptosis Detection Kit (Beyotime), followed by flow cytometry. For cell cycle analysis, A375 cells were treated with either BR or UVA or both, fixed with 70% ethanol, incubated with propidium iodide (PI) and RNase A mixture, and analyzed by flow cytometry (Becton Dickinson, USA).

2.8. Xenograft Assay in Nude Mice

Athymic nude (nu/nu) mice were obtained from Chongqing Medical University. 4-week-old male mice were injected with A375 cells (3 × 106 cells) in the right flanks into the subdermal space. Tumor volumes were estimated every other day by caliper measurements, and tumor volumes were calculated by the formula (volume = tumor length in mm × width2 in mm × 0.5236). Once tumors reached a mean volume of 30–50 mm3, mice were randomly allocated into four groups and treated with either DMSO or BR (2 mg/kg) or UVA (75 kJ/m2) and in combination of BR and UVA every other day for seven days. Mice were sacrificed, and tumors were dissected. Formalin-fixed, paraffin-embedded tumor tissue sections were used for IHC, whereas snap-frozen tissues were subjected to Western blot analysis.

2.9. qRT-PCR

Incubation of A375 cells was performed with UVA, BR, or both for times indicated. Treated cells were lysed with TRIzol (Takara) for total RNA purification. Reverse transcription was performed using Go Script™ Reverse Transcription System (Promega). The qPCR analysis was performed by using a RT2 SYBR Green/Fluorescein PCR Master Mix (Promega) on an iQ5 real-time PCR system (Bio-Rad) with oligonucleotide primer pairs to detect various genes. All samples were normalized to GAPDH mRNA levels, and relative mRNA expressions were analyzed using 2−△△Ct method as described previously [41].

2.10. Colony Formation Assay

A375 cells were plated at densities of 500 cells per well in 6-well plates. After 24 hours of incubation, cells were exposed to UVA (75 kJ/m2) and/or BR (50 nM) and the colonies formed were photographed after one week. Colonies were confirmed only if a single clone contained more than 50 cells. Fresh DMEM (10% FBS) was replaced every 72 hours.

2.11. Statistical Analysis

All experiments were performed three times in independent experiments to obtain reproducible results. Statistical data were subjected to analysis of variance (ANOVA) following Tukey’s test to analyze the differences. A value of <0.05 was considered as statistically significant.

3. Results

3.1. Low-Dose UVA Modulates the Expression of Phase II Detoxification Enzyme

To explore the effect of UVA on growth of melanoma cells, A375 melanoma cells were treated with different doses of UVA. Low dose of UVA irradiation did not significantly affect survival of cells at UVA doses of up to 100 kJ/m2 (Figure 1(a)). Western blot results showed that these doses of UVA irradiation induced the expression of Nrf2, HO-1, and GSTP1 proteins, with slight induction of NQO1 protein (Figure 1(b)). We chose the low dose of 75 kJ/m2 for the following experiments since cell survival at this dose was not affected but caused an increase in the protein levels of HO-1 and a slight increase of the GSTP1 and NQO1 (Figure 1(b)).

Nrf2 and NF-κB are transcription factors. It was previously reported that Nrf2 and NF-κB simultaneously accumulate in the cell nucleus and NF-κB (p65) antagonizes Nrf2-induced gene transcription [42]. Conversely, some phase II-inducers (enzyme) activate the signaling and inhibit NF-κB pathway [43]. To understand the relationship between Nrf2 and NF-κB in our experimental setup, we analyzed the NF-κB signaling pathway by Western blot assay. NF-κB and COX2 expression were slightly increased following UVA irradiation in a dose-dependent manner (Figure 1(c)). However, the levels of IκBα as NF-κB target proteins were not affected by UVA irradiation (Figure 1(c)), indicating that this low-dose UVA irradiation does not significantly affect the NF-κB signaling pathway.

3.2. BR Potentially Inhibits the Nrf2 Signaling Pathway

First, we examined the effect of BR on cell viability. A375 cells were treated with a concentration range of BR (0–100 nM), and the proliferation rates of A375 cell were slightly reduced in a dose-dependent manner (Figure 2(a)). To confirm that BR inhibits the Nrf2 pathway in A375 cells, whole-cell lysates were collected and protein expression levels were determined by Western blotting after treatment with BR. After 24 hours, BR caused a reduction of Nrf2 and GSTP1 protein levels in a concentration-dependent manner, whereas the levels of NQO1 remained relatively unchanged (Figure 2(b), right).

A time course of BR (50 nM) treatment of A375 cells showed an effect on the Nrf2 pathway and revealed that Nrf2 protein levels were significantly decreased at 2, 4, and 24 hours following the addition of BR, with maximal reduction at 4 hours (Figure 2(b), left). Significant changes in downstream targets of Nrf2, that is, HO-1 and NQO1, were not observed over the time course, whereas only a slight reduction in GSTP1 was observed (Figure 2(b), left). Further, we did not find that 50 nM BR had an effect on NF-κB and IκBα, whereas the COX2 protein levels were slightly increased compared to controls (Figure 2(c)). A previous study demonstrated that BR induces activation of NF-κB in HL-60 cell [44]. This difference in NF-κB activation is most likely due to a cell line-specific effect, and a concentration of 50 nM BR is required for this effect. These results suggest that the predominant effect of BR in A375 cells is a potential inhibition of the Nrf2 signaling pathway.

3.3. Cotreatment Increases Intracellular ROS Level and Inhibits A375 Cell Growth and Proliferation

We hypothesize that a relatively low-dose UVA irradiation of 75 kJ/m2 combined with 50 nM BR can affect cell survival in A375 cells. Therefore, we addressed the question whether cotreatment with UVA and BR resulted in lower cell survival in conjunction with elevated intracellular ROS levels and hence an increased sensitivity to BR treatment. Intracellular ROS levels were measured in A375 cells using flow cytometry. Low-dose UVA-treated A375 cells displayed slightly increased ROS levels compared to nontreated cells. Likewise, BR treatment increased intracellular ROS levels slightly, so that cotreatment further increased ROS levels (Figure 3(c)). To determine the efficacy of BR and UVA on cell growth, A375 cells were treated with BR or UVA and cell proliferation were counted by MTS. As shown in Figures 3(a) and 3(b), combination treatment significantly suppressed cell proliferation. We also check the proliferation marker Ki67 in BR- or UVA-treated cells, and the results were similar as that for cell survival (Supplementary Figure 1).

Furthermore, the cell cycle of A375 cells was analyzed by flow cytometry to examine whether cotreatment inhibits cell proliferation by inducing a cell cycle arrest. UVA treatment plus BR resulted in a marked increase in the percentage of A375 cells in the G1 phase (Figures 3(d) and 3(e)). To confirm these results, we analyzed the mRNA levels of cyclinD1, cyclinE2, CDK2, CDK4, and CDK6 which could promote A375 cells to pass the G1 to S phase checkpoint. We found that cyclinD1, cyclinE2, CDK4, and CDK6 were reduced following UVA/BR cotreatment, while CDK2 expression was increased (Figure 3(f)) at gene expression level, but this gene expression was different in translational level. Immunoblot assays revealed that cylinE2 and CDK2 were slightly decreased following UVA/BR cotreatment, but no significant change was seen in cyclinD1 expression (Figure 3(g)). Collectively, these results suggest that UVA is able to enhance BR-induced ROS levels and affects cell survival and the regulation of cell cycle-related proteins.

3.4. Cotreatment Blocks Nrf2 and AKT Signaling through Enhanced Cell Apoptosis

To explore whether the observed reduced cell viability of A375 cells was due to apoptosis, A375 melanoma cells and HaCaT skin keratinocytes were stained with Annexin V-FITC and PI and analyzed by flow cytometry. The results showed that HaCaT cells do not exert significant apoptosis after treatment with either BR alone or cotreatment under this condition (Supplementary Figure 2). In contrast, BR or cotreatment in A375 cells leads to significant apoptosis detected 24 hours post treatment, with a higher apoptosis rate in A375 cells after cotreatment (Figures 4(a) and 4(b)). Furthermore, UVA/BR cotreatment markedly suppressed protein levels of Bcl-2 and Bcl-xl and increased the expression levels of Bax. Consistent with these findings, UVA/BR cotreatment causes cleavage and activation of caspase-3, clearly indicating a marked increase in apoptosis rate (Figures 4(c) and 4(d)).

To evaluate the effect of cotreatment on the Nrf2 pathway in the presence of UVA, we performed immunoblot assays to detect protein levels of Nrf2 and its downstream genes. The expression levels of Nrf2, HO-1, and GSTP1 were decreased 24 hours following cotreatment compared with UVA or BR single treatment (Figure 4(e)). In addition, we found that AKT phosphorylation at position Ser473 was markedly reduced 24 hours after application of UVA/BR, whereas total AKT was not significantly changed (Figure 4(e)). These results indicate that cotreatment in A375 inhibits/AKT signaling while inhibiting Nrf2 expression. Similar results were obtained with camptothecin as another potential inhibitor of Nrf2 (data not shown) [45, 46].

3.5. Combination Treatment Inhibited Tumor Growth in Mice

Since the observed apoptosis induction by combined treatment with UVA/BR occurs in melanoma cells, but not in skin keratinocytes (HaCaT cells) under these conditions (data not show), we addressed the question whether a combination of UVA and BR can affect cell proliferation in melanoma-derived tumors in vitro and in vivo (Figure 5). For assessment of tumor growth in vitro, a colony formation assay was performed. Both BR alone and in combination with UVA reduced the number of colonies formed, while UVA has no significant effect on colony formation (Figures 5(a) and 5(b)). To explore the effect of UVA/BR cotreatment on tumor growth in vivo, A375 xenografts were grown in NOD/SCID mice as a heterotopic tumor model. NOD/SCID mice were injected with A375 cells (3 × 106 per injection site) to form a tumor. After 18 days, tumors reached volumes of about 30 to 50 mm3 and UVA (75 KJ/m2) irradiation or BR (2 mg/kg) was administered intraperitoneally every other day for 10 days [47]. Mice were covered with silver paper, contact and irradiate the tumors using a UVA lamp, and tumor growth was observed for 5 days after cessation of treatment. We observed a significant inhibition of tumor growth in vivo after cotreatment (Figures 5(c) and 5(d)) that was significantly higher than after single treatments of the tumors. Moreover, in one out of four cases treated with BR alone, a complete remission of the tumor and in two cases after UVA/BR cotreatment was observed. These observations demonstrate that cotreatment of melanoma-derived tumors reduced the tumor growth in vivo.

3.6. UVA Enhances Nrf2 Knockout-Mediated Cell Suppression

In addition to the pharmacological inhibition of Nrf2 using BR, we examined the effect of a genetic knockout of Nrf2 in A375 cells using the CRISPR/Cas9 method. Cas9 plasmids that expressed Nrf2 gRNA sequences against Nrf2 were used, and the clone number 1 identified bearing the knockdown, and Nrf2−/− clone number 2 exhibited the most significant reduction of Nrf2 protein expression (Figure 6(a)). Therefore, subsequent experiments were performed with this cell clone named Nrf2−/− while Cas9 clones of A375 cells were used as a control cell line for the knockout cell line. First, we determined whether UVA enhances intracellular ROS in A375 Nrf2 knockout cells leading to increased sensitivity against UVA treatment. Furthermore, we investigated intracellular ROS levels in Nrf2−/− cells following UVA irradiation and observed increased ROS levels compared to Nrf2−/− cells (Figure 6(b)).

To determine the efficacy of UVA on cell growth in Nrf2−/− cells, cells were treated with UVA (75 kJ/m2) and cell proliferation was quantified by MTS (Figure 6(c)). UVA irradiation suppressed proliferation of Nrf2−/− cells at 48 hours when compared to sham control, and the result of Nrf2−/− number 1 similar to Nrf2−/− number 2 (Supplementary Figures 3A and 3C). Furthermore, flow cytometry was used to examine whether UVA irradiation inhibits proliferation of Nrf2−/− cells by inducing cell cycle arrest. Representative histograms and combined results are summarized (Figures 6(d) and 6(e)). UVA treatment resulted in a marked increase of the percentage of G1 phase in Nrf2−/− cells at 48 hours (Figures 6(d) and 6(e)). To explore whether the reduced cell viability was due to apoptosis, Nrf2−/− cells were irradiated with UVA and flow cytometer analysis revealed no increase in apoptosis in Nrf2−/− cells (Figure 6(f)). To further assess the effect of UVA irradiation on Nrf2−/− cell proliferation, a colony formation assay was conducted. UVA irradiation has no effect on colony formation in Nrf2−/− cells (Figure 6(g)), and we also get the similar results in Nrf2−/− number 1 cell (Supplementary Figure 3B). These results demonstrate that this dose of UVA mediates cell suppression, but not apoptosis in Nrf2−/− cells. Previous studies suggested that 150 kJ/m2 UVA irradiation induced cell death in Nrf2-deficient murine dermal fibroblasts [33]. The different results may due to a difference in UVA dose (75 kJ/m2) applied in our study and to the variable UVA response in different cell lines.

4. Discussion

Nrf2 is a key player of the cellular defense against endogenous and exogenous chemical and oxidative insults. Exposure to chemicals may cause organ damage, so that the lung, liver, and kidney are significantly more affected in Nrf2 knockout mice than in their latter controls [48], hence made them highly prone to develop oxidative damage-related diseases and cancers. Moreover, Nrf2 has been proposed as an effective target for cancer chemoprevention and chemoresistance due to its linkage to pathways such as NF-κB pathway [49]. Recently, some studies reported that BR provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes hepatoma cells to chemical toxicity [13]. As demonstrated, increased levels of Nrf2 contribute to resistance in therapies (radio- and chemotherapy) in breast and lung cancer [49]; on the contrary, inhibition of Nrf2 may lead to enhanced efficacy of photo- or chemotherapy. In this study, we have shown that UVA enhances BR chemosensitivity in an additive fashion and that cotreatment inhibits cell proliferation and induces apoptosis in vitro and ameliorates melanoma growth in vivo.

BR is a broad spectrum anti-inflammatory agent that stabilizes lysosomal membranes, thereby reducing the release of hydrolytic enzymes that cause damage to surrounding tissues [50]. The anticancer properties of BR were demonstrated in lymphocytic leukemia, Ehrlich carcinoma, and hepatoma [5153] and are mainly due to a significant inhibition of chemoresistance-mediating Nrf2 gene and the resulting downstream target genes, thereby sensitizing tumor cells to chemo- and phototherapy [30, 31, 37]. Previously, it was reported that low concentrations of BR may inhibit general protein synthesis, but more recently, it was shown that BR acts as a Nrf2 pathway-specific inhibitor when used in an upper nanomolar range [19, 48, 53]. Here, we also demonstrated that BR when used in A375 melanoma cells in a range of 10–100 nM, specifically downregulated the protein level of Nrf2 and its target genes. Despite a moderate reduction of HO-1 and NQO1, we did not find a significant effect on the NF-κB and its target genes.

UVA can penetrate deeply into the subcutaneous layer and primarily induces cellular responses through oxidative stress (ROS) triggered by endogenous photosensitization of the drug. UVA alone or in combination with photoreactive drugs can lead to ROS-mediated damage of biomolecules including DNA [54]. For instance, psoralen plus UVA (PUVA), a nontoxic photoreactive drug, is activated by subsequent exposure to UVA light, which causes extensive DNA damage leading to extensive tumor cell death, and clinically used to treat psoriasis as well as head and neck cancers [39, 55]. Recently, berberine has been reported to be a photosensitive drug and can be used in photodynamic therapy (PDT) to treat cancer cells, where the photosensitive drug is activated upon exposure to UVA, causing massive DNA strand breaks in tumor cells [56]. In addition, low concentration of S4TdR when combined with nonlethal doses of UVA kills hyperproliferative or cancerous skin cells [39].

In this study, we found that cotreatment (UVA + BR) elevated intracellular ROS and induced the Akt pathway by inhibition of Akt phosphorylation at Ser473 [57]. The Akt/PI3K pathway forms an important component of cell survival mechanisms [58, 59], and previous reports demonstrated functional interactions with Nrf2 activation [6062]. Similarly, our results revealed that Akt phosphorylation was decreased with Nrf2 suppression in A375 cells with cotreatment.

Previously, it was demonstrated that a decrease in Nrf2 activity is associated with chemotherapeutic efficacy in mice after chronic administration of BR [30, 31]. We found that either BR alone or in a regimen with UVA and BR abolished the clonogenicity of melanoma cells. The tumor xenograft experiments in nude mice revealed that unlike cotreatment, treatment of either UVA or BR alone has an inhibitory effect on melanoma growth. However, Zhang and colleagues found that cisplatin or BR alone showed no significant inhibition of tumor growth in A549 xenografts. The difference in our results may be due to the experimental conditions or in the cell lines used.

We conclude that UVA/BR cotreatment inhibited melanoma cell growth and proliferation both in vitro and in vivo. Furthermore, we identified the AKT-Nrf2 pathway as mechanistically relevant for the observed antitumor effect of UVA and BR when both are combined. Therefore, we propose the usage of UVA and BR in combination as a novel treatment regimen for malignant melanomas thereby causing a prominent antitumor effect via regulation of AKT-Nrf2 pathway (summarized in Figure 7).

Conflicts of Interest

The authors declare no conflict of interest.


This work was supported by the National Natural Science Foundation of China (81271776 and 81573073), Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher Education (ODBS-2014-004), and Graduate Student Research Innovation Project (CYB16040). The authors thank Professor Xianjun Qu, Capital Medical University, for the useful discussion.

Supplementary Materials

Supplementary Figure 1: cotreatment inhibited Ki67 expression. Immunofluorescence assay was used to analyze cell proliferation marker Ki67 and its expression in UVA- and BR-treated cells for 48 hours. Supplementary Figure 2: cotreatment has no effect on keratinocyte apoptosis. (A and B) Keratinocyte HaCaT cells were treated with UVA and BR for 24 hours before measuring apoptosis using Annexin V and PI in conjunction with flow cytometry. Supplementary Figure 3: UVA irradiation inhibited Nrf2−/− number 1 A375 cell proliferation. (A) A375 Nrf2−/− number 1 irradiated with 75 kJ/m2 UVA, followed by MTS assay. (B) Cell cycle-related genes cyclinE2, CDK4, and CDK6 were performed by qRT-PCR assay. (C) Colony formation was examined by staining colonies with crystal violet. Colonies with more than 50 cells were counted (). (Supplementary Materials)


  1. J. Mounessa, T. Buntinx-Krieg, R. Qin, C. A. Dunnick, and R. P. Dellavalle, “Primary and secondary chemoprevention of malignant melanoma,” American Journal of Clinical Dermatology, vol. 17, no. 6, pp. 625–634, 2016. View at: Publisher Site | Google Scholar
  2. M. Constantinou, “Melanoma genomics and immunotherapy,” Rhode Island Medical Journal, vol. 98, no. 11, pp. 31–34, 2015. View at: Google Scholar
  3. H. Swalwell, J. Latimer, R. M. Haywood, and M. A. Birch-Machin, “Investigating the role of melanin in UVA/UVB- and hydrogen peroxide-induced cellular and mitochondrial ROS production and mitochondrial DNA damage in human melanoma cells,” Free Radical Biology & Medicine, vol. 52, no. 3, pp. 626–634, 2012. View at: Publisher Site | Google Scholar
  4. G. Merlino, M. Herlyn, D. E. Fisher et al., “The state of melanoma: challenges and opportunities,” Pigment Cell & Melanoma Research, vol. 29, no. 4, pp. 404–416, 2016. View at: Publisher Site | Google Scholar
  5. K. E. Mercer and C. A. Pritchard, “Raf proteins and cancer: B-Raf is identified as a mutational target,” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol. 1653, no. 1, pp. 25–40, 2003. View at: Publisher Site | Google Scholar
  6. M. Maroti, E. Ulff, J. Lyth, and U. Falkmer, “A prospective population-based study, aiming to support decision-making in a follow-up programme for patients with cutaneous malignant melanoma, based on patterns of recurrence,” European Journal of Dermatology, vol. 26, no. 6, pp. 586–591, 2016. View at: Publisher Site | Google Scholar
  7. S. Mourah and C. Lebbe, “Molecular alterations in melanoma and targeted therapies,” Bulletin du Cancer, vol. 101, Supplement 2, pp. S5–S11, 2014. View at: Publisher Site | Google Scholar
  8. H. R. Hintsala, E. Jokinen, K. M. Haapasaari et al., “Nrf2/Keap1 pathway and expression of oxidative stress lesions 8-hydroxy-2-deoxyguanosine and nitrotyrosine in melanoma,” Anticancer Research, vol. 36, no. 4, pp. 1497–1506, 2016. View at: Google Scholar
  9. S. Reuter, S. C. Gupta, M. M. Chaturvedi, and B. B. Aggarwal, “Oxidative stress, inflammation, and cancer: how are they linked?” Free Radical Biology & Medicine, vol. 49, no. 11, pp. 1603–1616, 2010. View at: Publisher Site | Google Scholar
  10. X. F. Hu, J. Yao, S. G. Gao et al., “Nrf2 overexpression predicts prognosis and 5-FU resistance in gastric cancer,” Asian Pacific Journal of Cancer Prevention, vol. 14, no. 9, pp. 5231–5235, 2013. View at: Publisher Site | Google Scholar
  11. S. Sukumari-Ramesh, N. Prasad, C. H. Alleyne, J. R. Vender, and K. M. Dhandapani, “Overexpression of Nrf2 attenuates carmustine-induced cytotoxicity in U87MG human glioma cells,” BMC Cancer, vol. 15, no. 1, 2015. View at: Publisher Site | Google Scholar
  12. I. Gañán-Gómez, Y. Wei, H. Yang, M. C. Boyano-Adánez, and G. García-Manero, “Oncogenic functions of the transcription factor Nrf2,” Free Radical Biology & Medicine, vol. 65, pp. 750–764, 2013. View at: Publisher Site | Google Scholar
  13. A. Olayanju, I. M. Copple, H. K. Bryan et al., “Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity—implications for therapeutic targeting of Nrf2,” Free Radical Biology & Medicine, vol. 78, pp. 202–212, 2015. View at: Publisher Site | Google Scholar
  14. J. H. No, Y. B. Kim, and Y. S. Song, “Targeting Nrf2 signaling to combat chemoresistance,” Journal of Cancer Prevention, vol. 19, no. 2, pp. 111–117, 2014. View at: Publisher Site | Google Scholar
  15. A. Uruno and H. Motohashi, “The Keap1-Nrf2 system as an in vivo sensor for electrophiles,” Nitric Oxide, vol. 25, no. 2, pp. 153–160, 2011. View at: Publisher Site | Google Scholar
  16. M. K. Kwak, N. Wakabayashi, and T. W. Kensler, “Chemoprevention through the Keap1–Nrf2 signaling pathway by phase 2 enzyme inducers,” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 555, no. 1-2, pp. 133–148, 2004. View at: Publisher Site | Google Scholar
  17. T. Shibata, T. Ohta, K. I. Tong et al., “Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 36, pp. 13568–13573, 2008. View at: Publisher Site | Google Scholar
  18. T. Suzuki, H. Motohashi, and M. Yamamoto, “Toward clinical application of the Keap1-Nrf2 pathway,” Trends in Pharmacological Sciences, vol. 34, no. 6, pp. 340–6, 2013. View at: Publisher Site | Google Scholar
  19. X. J. Wang, Z. Sun, N. F. Villeneuve et al., “Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2,” Carcinogenesis, vol. 29, no. 6, pp. 1235–1243, 2008. View at: Publisher Site | Google Scholar
  20. S. Lee, M. J. Lim, M. H. Kim et al., “An effective strategy for increasing the radiosensitivity of human lung cancer cells by blocking Nrf2-dependent antioxidant responses,” Free Radical Biology & Medicine, vol. 53, no. 4, pp. 807–816, 2012. View at: Publisher Site | Google Scholar
  21. P. Zhang, A. Singh, S. Yegnasubramanian et al., “Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth,” Molecular Cancer Therapeutics, vol. 9, no. 2, pp. 336–346, 2010. View at: Publisher Site | Google Scholar
  22. K. Chan, X. D. Han, and Y. W. Kan, “An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 8, pp. 4611–4616, 2001. View at: Publisher Site | Google Scholar
  23. L. M. Aleksunes, M. J. Goedken, C. E. Rockwell, J. Thomale, J. E. Manautou, and C. D. Klaassen, “Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity,” The Journal of Pharmacology and Experimental Therapeutics, vol. 335, no. 1, pp. 2–12, 2010. View at: Publisher Site | Google Scholar
  24. H. Y. Cho, S. P. Reddy, M. Yamamoto, and S. R. Kleeberger, “The transcription factor NRF2 protects against pulmonary fibrosis,” FASEB Journal, vol. 18, no. 9, pp. 1258–1260, 2004. View at: Publisher Site | Google Scholar
  25. J. Zhu, H. Wang, F. Chen et al., “An overview of chemical inhibitors of the Nrf2-ARE signaling pathway and their potential applications in cancer therapy,” Free Radical Biology & Medicine, vol. 99, pp. 544–556, 2016. View at: Publisher Site | Google Scholar
  26. W. Tang, J. Xie, S. Xu et al., “Novel nitric oxide-releasing derivatives of brusatol as anti-inflammatory agents: design, synthesis, biological evaluation, and nitric oxide release studies,” Journal of Medicinal Chemistry, vol. 57, no. 18, pp. 7600–7612, 2014. View at: Publisher Site | Google Scholar
  27. S. T. Lau, Z. X. Lin, Y. Liao, M. Zhao, C. H. K. Cheng, and P. S. Leung, “Bruceine D induces apoptosis in pancreatic adenocarcinoma cell line PANC-1 through the activation of p38-mitogen activated protein kinase,” Cancer Letters, vol. 281, no. 1, pp. 42–52, 2009. View at: Publisher Site | Google Scholar
  28. S. T. Lau, Z. X. Lin, M. Zhao, and P. S. Leung, “Brucea javanica fruit induces cytotoxicity and apoptosis in pancreatic adenocarcinoma cell lines,” Phytotherapy Research, vol. 22, no. 4, pp. 477–486, 2008. View at: Publisher Site | Google Scholar
  29. E. Mata-Greenwood, M. Cuendet, D. Sher, D. Gustin, W. Stock, and J. M. Pezzuto, “Brusatol-mediated induction of leukemic cell differentiation and G1 arrest is associated with down-regulation of c-myc,” Leukemia, vol. 16, no. 11, pp. 2275–2284, 2002. View at: Publisher Site | Google Scholar
  30. D. Ren, N. F. Villeneuve, T. Jiang et al., “Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 4, pp. 1433–1438, 2011. View at: Publisher Site | Google Scholar
  31. S. Tao, S. Wang, S. J. Moghaddam et al., “Oncogenic KRAS confers chemoresistance by upregulating NRF2,” Cancer Research, vol. 74, no. 24, pp. 7430–7441, 2014. View at: Publisher Site | Google Scholar
  32. T. Wu, B. G. Harder, P. K. Wong, J. E. Lang, and D. D. Zhang, “Oxidative stress, mammospheres and Nrf2-new implication for breast cancer therapy?” Molecular Carcinogenesis, vol. 54, no. 11, pp. 1494–1502, 2015. View at: Publisher Site | Google Scholar
  33. B. Harder, W. Tian, J. J. la Clair et al., “Brusatol overcomes chemoresistance through inhibition of protein translation,” Molecular Carcinogenesis, vol. 56, no. 5, pp. 1493–1500, 2017. View at: Publisher Site | Google Scholar
  34. J. L. Zhong, C. M. Raval, M. F. Nisar et al., “Development of refractoriness of HO-1 induction to a second treatment with UVA radiation and the involvement of Nrf2 in human skin fibroblasts,” Photochemistry and Photobiology, vol. 90, no. 6, pp. 1340–1348, 2014. View at: Publisher Site | Google Scholar
  35. A. Hirota, Y. Kawachi, K. Itoh et al., “Ultraviolet A irradiation induces NF-E2-related factor 2 activation in dermal fibroblasts: protective role in UVA-induced apoptosis,” The Journal of Investigative Dermatology, vol. 124, no. 4, pp. 825–832, 2005. View at: Publisher Site | Google Scholar
  36. G. J. Clydesdale, G. W. Dandie, and H. K. Muller, “Ultraviolet light induced injury: immunological and inflammatory effects,” Immunology and Cell Biology, vol. 79, no. 6, pp. 547–568, 2001. View at: Publisher Site | Google Scholar
  37. F. R. de Gruijl, “[33] photocarcinogenesis: UVA vs UVB,” Methods in Enzymology, vol. 319, pp. 359–366, 2000. View at: Publisher Site | Google Scholar
  38. A. Svobodova, D. Walterova, and J. Vostalova, “Ultraviolet light induced alteration to the skin,” Biomedical Papers, vol. 150, no. 1, pp. 25–38, 2006. View at: Publisher Site | Google Scholar
  39. O. Reelfs, Y. Z. Xu, A. Massey, P. Karran, and A. Storey, “Thiothymidine plus low-dose UVA kills hyperproliferative human skin cells independently of their human papilloma virus status,” Molecular Cancer Therapeutics, vol. 6, no. 9, pp. 2487–2495, 2007. View at: Publisher Site | Google Scholar
  40. E. Piskounova, M. Agathocleous, M. M. Murphy et al., “Oxidative stress inhibits distant metastasis by human melanoma cells,” Nature, vol. 527, no. 7577, pp. 186–191, 2015. View at: Publisher Site | Google Scholar
  41. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001. View at: Publisher Site | Google Scholar
  42. W. Li, T. O. Khor, C. Xu et al., “Activation of Nrf2-antioxidant signaling attenuates NFκB-inflammatory response and elicits apoptosis,” Biochemical Pharmacology, vol. 76, no. 11, pp. 1485–1489, 2008. View at: Publisher Site | Google Scholar
  43. M. Buelna-Chontal and C. Zazueta, “Redox activation of Nrf2 & NF-κB: a double end sword?” Cellular Signalling, vol. 25, no. 12, pp. 2548–2557, 2013. View at: Publisher Site | Google Scholar
  44. M. Cuendet, J. J. Gills, and J. M. Pezzuto, “Brusatol-induced HL-60 cell differentiation involves NF-κB activation,” Cancer Letters, vol. 206, no. 1, pp. 43–50, 2004. View at: Publisher Site | Google Scholar
  45. F. Chen, H. Wang, J. Zhu et al., “Camptothecin suppresses NRF2-ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs,” British Journal of Cancer, vol. 117, no. 10, pp. 1495–1506, 2017. View at: Publisher Site | Google Scholar
  46. R. P. Verma and C. Hansch, “Camptothecins: a SAR/QSAR study,” Chemical Reviews, vol. 109, no. 1, pp. 213–235, 2009. View at: Publisher Site | Google Scholar
  47. Y. Ma, X. Li, A. Li, P. Yang, C. Zhang, and B. Tang, “H2S-Activable MOF nanoparticle photosensitizer for effective photodynamic therapy against cancer with controllable singlet-oxygen release,” Angewandte Chemie, vol. 56, no. 44, pp. 13752–13756, 2017. View at: Publisher Site | Google Scholar
  48. H. Y. Cho and S. R. Kleeberger, “Nrf2 protects against airway disorders,” Toxicology and Applied Pharmacology, vol. 244, no. 1, pp. 43–56, 2010. View at: Publisher Site | Google Scholar
  49. S. Zhou, W. Ye, Q. Shao, M. Zhang, and J. Liang, “Nrf2 is a potential therapeutic target in radioresistance in human cancer,” Critical Reviews in Oncology Hematology, vol. 88, no. 3, pp. 706–715, 2013. View at: Publisher Site | Google Scholar
  50. I. H. Hall, K. H. Lee, Y. Imakura, M. Okano, and A. Johnson, “Anti-inflammatory agents III: structure-activity relationships of brusatol and related quassinoids,” Journal of Pharmaceutical Sciences, vol. 72, no. 11, pp. 1282–1284, 1983. View at: Publisher Site | Google Scholar
  51. K. H. Lee, M. Okano, I. H. Hall, D. A. Brent, and B. Soltmann, “Antitumor agents XLV: bisbrusatolyl and brusatolyl esters and related compounds as novel potent antileukemic agents,” Journal of Pharmaceutical Sciences, vol. 71, no. 3, pp. 338–345, 1982. View at: Publisher Site | Google Scholar
  52. Y. F. Liou, I. H. Hall, M. Okano, K. H. Lee, and S. G. Chaney, “Antitumor agents XLVIII: structure-activity relationships of quassinoids as in vitro protein synthesis inhibitors of P-388 lymphocytic leukemia tumor cell metabolism,” Journal of Pharmaceutical Sciences, vol. 71, no. 4, pp. 430–435, 1982. View at: Publisher Site | Google Scholar
  53. I. H. Hall, Y. F. Liou, K. H. Lee, S. G. Chaney, and W. Willingham Jr., “Antitumor agents LIX: effects of quassinoids on protein synthesis of a number of murine tumors and normal cells,” Journal of Pharmaceutical Sciences, vol. 72, no. 6, pp. 626–630, 1983. View at: Publisher Site | Google Scholar
  54. O. Reelfs, V. Abbate, R. C. Hider, and C. Pourzand, “A powerful mitochondria-targeted iron chelator affords high photoprotection against solar ultraviolet a radiation,” The Journal of Investigative Dermatology, vol. 136, no. 8, pp. 1692–1700, 2016. View at: Publisher Site | Google Scholar
  55. S. Hackenberg, A. Scherzed, M. Kessler et al., “Zinc oxide nanoparticles induce photocatalytic cell death in human head and neck squamous cell carcinoma cell lines in vitro,” International Journal of Oncology, vol. 37, no. 6, pp. 1583–1590, 2010. View at: Publisher Site | Google Scholar
  56. N. Luiza Andreazza, C. Vevert-Bizet, G. Bourg-Heckly, F. Sureau, M. José Salvador, and S. Bonneau, “Berberine as a photosensitizing agent for antitumoral photodynamic therapy: insights into its association to low density lipoproteins,” International Journal of Pharmaceutics, vol. 510, no. 1, pp. 240–249, 2016. View at: Publisher Site | Google Scholar
  57. Y. Y. He, S. E. Council, L. Feng, and C. F. Chignell, “UVA-induced cell cycle progression is mediated by a disintegrin and metalloprotease/epidermal growth factor receptor/AKT/cyclin D1 pathways in keratinocytes,” Cancer Research, vol. 68, no. 10, pp. 3752–3758, 2008. View at: Publisher Site | Google Scholar
  58. B. D. Manning and L. C. Cantley, “AKT/PKB signaling: navigating downstream,” Cell, vol. 129, no. 7, pp. 1261–1274, 2007. View at: Publisher Site | Google Scholar
  59. R. M. Uranga, S. Katz, and G. A. Salvador, “Enhanced phosphatidylinositol 3-kinase (PI3K)/Akt signaling has pleiotropic targets in hippocampal neurons exposed to iron-induced oxidative stress,” The Journal of Biological Chemistry, vol. 288, no. 27, pp. 19773–19784, 2013. View at: Publisher Site | Google Scholar
  60. M. H. Li, Y. N. Cha, and Y. J. Surh, “Peroxynitrite induces HO-1 expression via PI3K/Akt-dependent activation of NF-E2-related factor 2 in PC12 cells,” Free Radical Biology & Medicine, vol. 41, no. 7, pp. 1079–1091, 2006. View at: Publisher Site | Google Scholar
  61. F. Rizvi, S. Shukla, and P. Kakkar, “Essential role of PH domain and leucine-rich repeat protein phosphatase 2 in Nrf2 suppression via modulation of Akt/GSK3β/Fyn kinase axis during oxidative hepatocellular toxicity,” Cell Death & Disease, vol. 5, article e1153, 2014. View at: Publisher Site | Google Scholar
  62. L. Wang, Y. Chen, P. Sternberg, and J. Cai, “Essential roles of the PI3 kinase/Akt pathway in regulating Nrf2-dependent antioxidant functions in the RPE,” Investigative Ophthalmology & Visual Science, vol. 49, no. 4, pp. 1671–1678, 2008. View at: Publisher Site | Google Scholar

Copyright © 2018 Mei Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.